Loading...

Home
Stock
EDAP

EDAP Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

4.260

Open

4.190

VWAP

4.14

Vol

65.07K

Mkt Cap

154.80M

Low

4.045

Amount

269.70K

EV/EBITDA(TTM)

--

Total Shares

37.48M

EV

164.75M

EV/OCF(TTM)

--

P/S(TTM)

2.09

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

Show More

Events Timeline

(ET)

2026-03-25

16:30:00

EDAP TMS Files $125M Mixed Securities Shelf

2026-03-25

16:30:00

Major Averages Rise on U.S. Iran Peace Plan

2026-03-25

12:10:00

U.S. Offers Iran 15-Point Peace Plan, Oil Prices Drop

2026-03-25

07:50:00

Rhodes Expects Continued Demand Growth for Focal One in Prostate Cancer Treatment

2026-03-25

07:50:00

Focal One Reports Q4 Revenue of $21.88M, Exceeds Expectations

2026-02-12 (ET)

2026-02-12

07:40:00

EDAP TMS Appoints David Horn to Board of Directors

2026-01-12 (ET)

2026-01-12

07:40:00

Focal One CEO: Strong Finish to 2025, HIFU Revenue Exceeds Half of Annual Revenue

2026-01-12

07:40:00

FY26 Combined Non-Core Business Revenue Expected Between $22.0M and $26.0M

2025-11-20 (ET)

2025-11-20

07:33:12

EDAP TMS Secures FDA 510(k) Approval for Focal One Robotic HIFU

News

seekingalpha

05-07seekingalpha

EDAP TMS S.A. Reports Record Q1 2026 Earnings Driven by HIFU Sales

Record Revenue: EDAP TMS S.A. reported total revenue of $17.8 million for Q1 2026, exceeding analysts' expectations of $16.6 million, primarily driven by Focal One robotic HIFU sales reaching $11.6 million, demonstrating the company's successful shift to higher-margin business segments.
Multi-Site Expansion: The company has now seen 11 U.S. hospitals and health networks invest in and launch two or more Focal One robotic HIFU programs, indicating a significant increase in market penetration that is expected to further drive future revenue growth.
International Momentum: Following the French National Health System's decision to provide universal coverage for the Focal One HIFU procedure, EDAP achieved its first cash sale in France, marking a pivotal expansion in its global operations and revenue diversification.
Stable Financial Outlook: The company reiterated its 2026 core HIFU revenue guidance of $50 million to $54 million, representing a 34% to 45% year-over-year growth, while also securing approximately $14 million from the European Investment Bank credit facility at the end of Q1, enhancing its financial flexibility.

seekingalpha

05-07seekingalpha

EDAP TMS S.A. Q1 Earnings Highlights

Earnings Performance: EDAP TMS S.A. reported a Q1 GAAP EPS of -$0.24, missing expectations by $0.01, while revenue reached $17.81 million, reflecting a 24.5% year-over-year increase and exceeding estimates by $1.21 million, indicating strong revenue growth momentum.
HIFU Revenue Growth: The company experienced a 78% year-over-year increase in HIFU revenue for Q1, demonstrating sustained market demand for this business line and reinforcing its position in the high-intensity focused ultrasound treatment sector.
U.S. HIFU Procedures Growth: There was a 53% year-over-year growth in U.S. HIFU procedures in Q1, showcasing the effectiveness of the company's expansion strategy in the U.S. market, which is expected to drive future revenue growth.
Future Outlook: The company reiterated its revenue guidance, projecting core HIFU business revenue to be between $50 million and $54 million, representing a year-over-year growth of 34% to 45%, while non-core business revenue is expected to range from $22 million to $26 million, reflecting confidence in future growth prospects.

Newsfilter

05-07Newsfilter

EDAP Reports Record First Quarter HIFU Revenue Growth

HIFU Revenue Surge: EDAP achieved $11.6 million in HIFU revenue for Q1 2026, marking a 78% year-over-year increase, which reflects the company's strong performance in a high-growth market and is expected to enhance shareholder value.
Record Procedure Volumes: U.S. Focal One procedure volumes grew by 53% year-over-year, reaching record levels, indicating the company's success in market penetration and customer demand, thereby strengthening its competitive position in the medical device sector.
International Market Expansion: The company secured capital sales of Focal One systems in the UK, France, and Hungary, marking the first time hospitals are investing in these systems for treating prostate cancer and deep infiltrating endometriosis, highlighting strategic international growth.
HIFI-2 Study Results: The HIFI-2 study results demonstrate the potential of Focal One HIFU for treating men with recurrent prostate cancer, further solidifying its market position as a non-invasive treatment option and signaling future growth opportunities.

seekingalpha

05-06seekingalpha

EDAP TMS S.A. to Announce Q1 Earnings on May 7

Earnings Announcement: EDAP TMS S.A. is set to release its Q1 2023 earnings on May 7 before market open, with a consensus EPS estimate of -$0.21, reflecting a 10.5% year-over-year decline, indicating profitability challenges ahead.
Revenue Expectations: Analysts project revenue to reach $16.6 million, representing a 16.1% year-over-year increase, suggesting that despite challenges, the company maintains a positive trajectory in revenue growth.
Historical Performance Review: Over the past year, EDAP has only beaten EPS estimates 25% of the time and has not exceeded revenue expectations, highlighting volatility in the company's profitability and revenue generation.
Future Outlook: EDAP TMS aims for $50 million to $54 million in HIFU revenue by 2026, indicating ongoing strategic expansion in both U.S. and international markets.

Newsfilter

04-16Newsfilter

EDAP to Announce Q1 2026 Financial Results on May 7

Earnings Announcement: EDAP TMS SA will release its Q1 2026 financial results before market open on May 7, 2026, reflecting the company's commitment to transparency and investor communication.
Conference Call Details: A conference call will be held on the same day at 8:30 AM EDT, hosted by CEO Ryan Rhodes and other executives, aimed at providing investors with an in-depth analysis of the financial results and future outlook.
Technological Leadership: EDAP TMS is a global leader in robotic energy-based therapies, developing and distributing various minimally invasive medical devices, showcasing its ongoing efforts in medical technology innovation.
Focal One® Product Overview: The Focal One® system is widely used in Europe and the U.S. for prostate focal therapy, with potential expansion into other indications, further solidifying its market position.

Yahoo Finance

03-25Yahoo Finance

EDAP Reports 39% Revenue Growth in HIFU for 2025

HIFU Revenue Growth: EDAP achieved a 39% revenue increase in its core HIFU business for 2025, reaching EUR 33.1 million, primarily driven by strong demand in the U.S. market, demonstrating the company's market penetration capabilities in high-growth sectors.
Global Sales Milestone: In Q4 2025, EDAP recorded 15 Focal One device placements worldwide, with 14 being cash sales, marking a robust performance in equipment sales and further solidifying its market leadership position.
Financial Challenges: Despite the growth in HIFU revenue, total revenue for 2025 was EUR 62.4 million, a 3% decline year-over-year, primarily due to a 27% drop in non-core distribution and ESWL businesses, which poses pressure on the company's overall financial health.
Future Outlook: The company expects HIFU revenue in 2026 to range from USD 50 million to USD 54 million, representing a growth of 34% to 45%, and plans to transition to a new ultrasound engine to mitigate tariff impacts, thereby enhancing margins and competitive positioning.

Wall Street analysts forecast EDAP stock price to rise

2 Analyst Rating

Wall Street analysts forecast EDAP stock price to rise

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

8.25

High

14.00

Current: 0.000

Low

2.50

Averages

8.25

High

14.00

H.C. Wainwright

Swayampakula Ramakanth

Buy

downgrade

$14 -> $10

AI Analysis

2026-04-09

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

$14 -> $10

AI Analysis

2026-04-09

downgrade

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on EDAP TMS to $10 from $14 and keeps a Buy rating on the shares. The firm says the company exited fiscal 2025 with two major milestones - establishing high-intensity focused ultrasound as its core business segment and becoming a U.S. domestic filer.

H.C. Wainwright

H.C. Wainwright

Buy

downgrade

$19 -> $14

2025-05-16

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$19 -> $14

2025-05-16

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on EDAP TMS to $14 from $19 and keeps a Buy rating on the shares following the Q1 report. The firm accounts for management's de-emphasizing the noncore businesses.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EDAP

Unlock Now

Valuation Metrics

The current forward P/E ratio for Edap Tms SA (EDAP.O) is 38.91, compared to its 5-year average forward P/E of -15.20. For a more detailed relative valuation and DCF analysis to assess Edap Tms SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-15.20

Current PE

38.91

Overvalued PE

41.51

Undervalued PE

-71.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-75.67

Current EV/EBITDA

-6.95

Overvalued EV/EBITDA

112.55

Undervalued EV/EBITDA

-263.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.09

Current PS

1.98

Overvalued PS

4.61

Undervalued PS

1.57

Financials

AI Analysis

Annual

Quarterly

Whales Holding EDAP

Soleus Capital Management, L.P.

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Edap Tms SA (EDAP) stock price today?

The current price of EDAP is 4.13 USD — it has decreased -0.72

What is Edap Tms SA (EDAP)'s business?

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

What is the price predicton of EDAP Stock?

Wall Street analysts forecast EDAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDAP is8.25 USD with a low forecast of 2.50 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Edap Tms SA (EDAP)'s revenue for the last quarter?

Edap Tms SA revenue for the last quarter amounts to 17.81M USD, increased 24.96

What is Edap Tms SA (EDAP)'s earnings per share (EPS) for the last quarter?

Edap Tms SA. EPS for the last quarter amounts to -0.24 USD, increased 20.00

How many employees does Edap Tms SA (EDAP). have?

Edap Tms SA (EDAP) has 289 emplpoyees as of May 11 2026.

What is Edap Tms SA (EDAP) market cap?

Today EDAP has the market capitalization of 154.80M USD.